Genovior Biotech Corporation
Update：2023/06/12
Industries
Main Industry
Biotechnology
Main Product/Service
1. process development of peptide or protein APIs from microbial or human recombinant fermentation processes
2. formulation development of biological injectable
3. manufacturing capacities of biological APIs, lyophilized injectable, and prefilled syringe/cartridge for preclinical, clinical, and commercial uses
2. formulation development of biological injectable
3. manufacturing capacities of biological APIs, lyophilized injectable, and prefilled syringe/cartridge for preclinical, clinical, and commercial uses
Founded Year
2015
Unified Business No.
24890496
Status
Active
Number of Employees
165
Total Paid-in
Capital
1,326,810,000 (NT$)
Location of Company
Taiwan
, Hsinchu County
Exit Status
Acquired(2025)
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Genovior is a dedicated CDMO focus on process development, scale up, formulation development, and productivity optimization under PIC/S GMP (cGMP, EU GMP) for our customers worldwide. Our one-stop services conveniently provide effective and efficient solution and our non-competition policy provides maximum security and protection in IP for our clients.
Genovior Biotech Corp. is a vertically integrated contract development and manufacture company, providing following services:
(a) process development of peptide or protein biologics from microbial or human recombinant fermentation processes
(b) formulation development of biological injectables
(c) manufacturing capacities of biologics, lyophilized injectable, and prefilled syringe/cartridge for preclinical, clinical, and commercial uses
Genovior Biotech Corp. is a vertically integrated contract development and manufacture company, providing following services:
(a) process development of peptide or protein biologics from microbial or human recombinant fermentation processes
(b) formulation development of biological injectables
(c) manufacturing capacities of biologics, lyophilized injectable, and prefilled syringe/cartridge for preclinical, clinical, and commercial uses
Corporate Video
